CL2021002761A1 - Micropartículas de liberación sostenida que contienen deslorelina, y método de preparación de las mismas - Google Patents

Micropartículas de liberación sostenida que contienen deslorelina, y método de preparación de las mismas

Info

Publication number
CL2021002761A1
CL2021002761A1 CL2021002761A CL2021002761A CL2021002761A1 CL 2021002761 A1 CL2021002761 A1 CL 2021002761A1 CL 2021002761 A CL2021002761 A CL 2021002761A CL 2021002761 A CL2021002761 A CL 2021002761A CL 2021002761 A1 CL2021002761 A1 CL 2021002761A1
Authority
CL
Chile
Prior art keywords
preparing
release microparticles
same
deslorelin
sustained release
Prior art date
Application number
CL2021002761A
Other languages
English (en)
Inventor
Ju Hee Kim
Se Yeon Kim
Original Assignee
Inventage Lab Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Inventage Lab Inc filed Critical Inventage Lab Inc
Publication of CL2021002761A1 publication Critical patent/CL2021002761A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/09—Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0021—Intradermal administration, e.g. through microneedle arrays, needleless injectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/113—Multiple emulsions, e.g. oil-in-water-in-oil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5089—Processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Dermatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dispersion Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

De acuerdo con las micropartículas de liberación sostenida que contienen deslorelina, y un método de preparación de las mismas, de la presente invención, se proporcionan micropartículas de liberación sostenida que contienen deslorelina en una formulación para la administración subcutánea, de modo que se puede aliviar el dolor durante la administración a los animales, y un efecto de castración química puede durar de 2 a 36 meses. Además, la presente invención es efectiva como agente de castración química durante 2 a 8 meses, de modo que tiene un excelente efecto de eliminación del olor a verraco.
CL2021002761A 2019-04-30 2021-10-20 Micropartículas de liberación sostenida que contienen deslorelina, y método de preparación de las mismas CL2021002761A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
KR1020190050437A KR102249104B1 (ko) 2019-04-30 2019-04-30 데슬로렐린을 포함하는 서방성 마이크로 입자 및 이의 제조 방법

Publications (1)

Publication Number Publication Date
CL2021002761A1 true CL2021002761A1 (es) 2022-06-03

Family

ID=73028838

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2021002761A CL2021002761A1 (es) 2019-04-30 2021-10-20 Micropartículas de liberación sostenida que contienen deslorelina, y método de preparación de las mismas

Country Status (15)

Country Link
US (1) US20220202894A1 (es)
EP (1) EP3949951A4 (es)
JP (1) JP7253287B2 (es)
KR (1) KR102249104B1 (es)
CN (1) CN113747884A (es)
AU (1) AU2020266058B2 (es)
BR (1) BR112021021599A2 (es)
CA (1) CA3137819C (es)
CL (1) CL2021002761A1 (es)
IL (1) IL287361A (es)
MX (1) MX2021012923A (es)
PE (1) PE20220491A1 (es)
SG (1) SG11202111521WA (es)
WO (1) WO2020222399A1 (es)
ZA (1) ZA202108300B (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20230124229A (ko) * 2022-02-18 2023-08-25 (주)인벤티지랩 데슬로렐린을 포함하는 서방성 주사용 조성물
WO2024003291A1 (en) 2022-06-30 2024-01-04 Virbac Deslorelin use in chemical castration of a non-human mammal related to pk/pd interaction
WO2024003288A1 (en) * 2022-06-30 2024-01-04 Virbac Deslorelin for attenuation of animal urine odor

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH1045625A (ja) * 1996-04-30 1998-02-17 Takeda Chem Ind Ltd 医薬組成物
EP1007080B1 (en) * 1996-08-30 2007-04-18 Peptech Limited Formulation for the sustained release of peptide agonists and analogues of GnRH
JP4166590B2 (ja) * 2003-02-04 2008-10-15 独立行政法人科学技術振興機構 ダブルエマルション・マイクロカプセル生成装置
DK1824460T3 (en) * 2004-11-10 2015-01-19 Tolmar Therapeutics Inc Stabilized polymeric delivery system
AU2007207618B2 (en) * 2006-01-18 2011-03-24 Foresee Pharmaceuticals Co., Ltd. Pharmaceutical compositions with enhanced stability
BRPI0902699A2 (pt) 2009-07-28 2011-04-12 Marcelo Vivacqua método quìmico para esterilização sexual e eliminação da libido em mamìferos do sexo masculino
KR101583351B1 (ko) * 2014-11-28 2016-01-07 동국제약 주식회사 초기 방출 억제 및 잔류용매 제거율을 향상시킨 서방출성 미립구 및 이의 제조방법
CN105287390A (zh) * 2015-11-20 2016-02-03 北京博恩特药业有限公司 一种长效醋酸亮丙瑞林微球及其制备方法
WO2017150824A1 (ko) * 2016-03-03 2017-09-08 가천대학교 산학협력단 마이크로 니들 및 이의 제조방법

Also Published As

Publication number Publication date
CA3137819A1 (en) 2020-11-05
US20220202894A1 (en) 2022-06-30
AU2020266058B2 (en) 2023-04-06
JP7253287B2 (ja) 2023-04-06
KR102249104B1 (ko) 2021-05-07
ZA202108300B (en) 2023-01-25
IL287361A (en) 2021-12-01
EP3949951A1 (en) 2022-02-09
BR112021021599A2 (pt) 2021-12-21
CN113747884A (zh) 2021-12-03
SG11202111521WA (en) 2021-11-29
WO2020222399A1 (ko) 2020-11-05
JP2022530878A (ja) 2022-07-04
KR20200126599A (ko) 2020-11-09
EP3949951A4 (en) 2023-01-18
CA3137819C (en) 2024-01-09
AU2020266058A1 (en) 2021-11-18
MX2021012923A (es) 2021-11-17
PE20220491A1 (es) 2022-04-07

Similar Documents

Publication Publication Date Title
CL2021002761A1 (es) Micropartículas de liberación sostenida que contienen deslorelina, y método de preparación de las mismas
ECSP19030002A (es) 1,2,4-triazolonas 2,4,5-trisustituidas
CO2017007003A2 (es) Formulaciones de sunitinib y métodos para uso de las mismas en el tratamiento de trastornos oculares
UY36665A (es) Derivados de ciclohexano sustituidos con amidas
AR102096A1 (es) Proceso para elaborar acetato de glatiramer
CL2020000220A1 (es) Composiciones que comprenden aminoácidos para su uso en el tratamiento de enfermedades relacionadas con la disfunción mitocondrial.
AR104212A1 (es) Formulaciones inyectables de liberación extendida que comprenden un agente activo de isoxazolina, métodos y usos de las mismas
CO2018007278A2 (es) Derivados de ácido aminobenzoico metaazacíclico como antagonistas de la integrina pan
PH12019502150A1 (en) Compounds and methods for the treatment of parasitic diseases
DOP2016000268A (es) Compuestos de azol amido–sustituidos como inhibidores de tnks1 y/o tnks2
CL2019002218A1 (es) Formulaciones de combinación triple y métodos para tratar o reducir el riesgo de enfermedad cardiovascular.
GT201700280A (es) Formulación sólida oral que contiene irinotecán y método de preparación de la misma
CL2019001746A1 (es) Amidas aromáticas de ácido carboxílico
CL2019002172A1 (es) Agente terapéutico para enfermedades del hígado.
AR120320A1 (es) Composiciones estéticas listas para usar
CL2018002287A1 (es) Derivados de tetrahidroisoquinolina.
PH12020500342A1 (en) New disinfectant for hatcheries
CL2020000221A1 (es) Composiciones que comprenden aminoácidos para su uso en el tratamiento de enfermedades relacionadas con la disfunción mitocondrial.
AR112844A1 (es) Composición de hidrogel a base de ácido hialurónico estabilizada farmacéuticamente y método de preparación de esta
AR101227A1 (es) Combinaciones de un derivado de n-tiazolil-4-fenoxibencenosulfonamida y un agente farmacéuticamente activo seleccionado a partir de gabapentina y pregabalina para tratar dolor
UA95686U (uk) Лікарський засіб для терапії захворювань передміхурової залози в формі супозиторія
CO2020002287A2 (es) Composiciones farmacéuticas
CO2021014967A2 (es) Composiciones farmacéuticas de combinación a dosis fijas de liberación inmediata, métodos y usos de las mismas
CO2022011987A2 (es) Usos y composiciones a base de polifenoles para mejorar la biodisponibilidad oral del hidroxitirol
UA122969U (uk) Антисептичний розчин для обробки дійок та вимені великої рогатої худоби